| pubmed-article:6660847 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6660847 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:6660847 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6660847 | lifeskim:mentions | umls-concept:C0149778 | lld:lifeskim |
| pubmed-article:6660847 | lifeskim:mentions | umls-concept:C0002645 | lld:lifeskim |
| pubmed-article:6660847 | lifeskim:mentions | umls-concept:C0055860 | lld:lifeskim |
| pubmed-article:6660847 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:6660847 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:6660847 | pubmed:dateCreated | 1984-2-14 | lld:pubmed |
| pubmed-article:6660847 | pubmed:abstractText | We compared responses to amoxicillin combined with clavulanic acid (ACA) with a cefaclor regimen in children with skin and soft tissue infections (impetigo and cellulitis) due to Staphylococcus aureus, Streptococcus pyogenes, and Haemophilus species. All isolates from the 41 patients we were able to evaluate were susceptible to ACA by disk susceptibility testing at the onset of treatment. The 21 children receiving ACA and 18 (90%) of 20 taking cefaclor responded to therapy. Clinical cure was achieved in 18 (86%) of 21 and 18 (90%) of 20 in the two groups, respectively. Bacteriological failure occurred in 2 (10%) patients in the cefaclor group and none in the group receiving ACA; however, there were 2 (9%) relapses and 1 (5%) reinfection among the 21 children taking ACA. Adverse effects, although mild, occurred more commonly (9 of 21 versus 1 of 20; P = 0.005) with ACA than with cefaclor. | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6660847 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6660847 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6660847 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6660847 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:6660847 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:6660847 | pubmed:author | pubmed-author:CamposJ MJM | lld:pubmed |
| pubmed-article:6660847 | pubmed:author | pubmed-author:FleisherG RGR | lld:pubmed |
| pubmed-article:6660847 | pubmed:author | pubmed-author:WilmottC MCM | lld:pubmed |
| pubmed-article:6660847 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6660847 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:6660847 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6660847 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6660847 | pubmed:pagination | 679-81 | lld:pubmed |
| pubmed-article:6660847 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:meshHeading | pubmed-meshheading:6660847-... | lld:pubmed |
| pubmed-article:6660847 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6660847 | pubmed:articleTitle | Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children. | lld:pubmed |
| pubmed-article:6660847 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6660847 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6660847 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6660847 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6660847 | lld:pubmed |
